Analysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (MREO) and PAVmed (PAVM)
TipRanks (Thu, 16-May 8:10 AM ET)
Analysts’ Opinions Are Mixed on These Healthcare Stocks: HUTCHMED (HCM) and PAVmed (PAVM)
TipRanks (Wed, 15-May 3:40 PM ET)
PAVmed (PAVM) Receives a Buy from Lake Street
TipRanks (Wed, 15-May 9:05 AM ET)
PAVmed Inc Provides Informal Financial Performance Update
TipRanks (Tue, 14-May 10:52 AM ET)
PAVmed Non-GAAP EPS of -$0.99 beats by $0.56, revenue of $1.01M misses by $0.03M
Seeking Alpha News (Tue, 14-May 2:51 AM ET)
PAVmed Provides Business Update and First Quarter 2024 Financial Results
PRNewswire (Mon, 13-May 8:43 PM ET)
PAVmed Q1 2024 Earnings Preview
Seeking Alpha News (Mon, 13-May 12:13 PM ET)
Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results
PRNewswire (Mon, 13-May 8:00 AM ET)
Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall
PRNewswire (Thu, 9-May 7:49 AM ET)
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The Company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
Pavmed trades on the NASDAQ stock market under the symbol PAVM.
As of May 17, 2024, PAVM stock price declined to $1.79 with 58,455 million shares trading.
PAVM has a beta of 1.92, meaning it tends to be more sensitive to market movements. PAVM has a correlation of 0.04 to the broad based SPY ETF.
PAVM has a market cap of $14.41 million. This is considered a Sub-Micro Cap stock.
Last quarter Pavmed reported $1 million in Revenue and -$.99 earnings per share. This fell short of revenue expectation by $-40,000 and exceeded earnings estimates by $.68.
In the last 3 years, PAVM stock traded as high as $145.50 and as low as $1.60.
The top ETF exchange traded funds that PAVM belongs to (by Net Assets): VTI, VXF.
PAVM has underperformed the market in the last year with a price return of -77.0% while the SPY ETF gained +30.7%. PAVM has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -18.6% and -20.1%, respectively, while the SPY returned +6.3% and +4.8%, respectively.
PAVM support price is $1.74 and resistance is $2.02 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PAVM stock will trade within this expected range on the day.